With the aim of improving viral distribution and tumor penetration, we have engineered decorin expressing replication-incompetent (dl-LacZ-DCNG) andcompetent (Ad-ΔE1B-DCNG) adenoviruses. In both tumor spheroids and established solid tumors in vivo, administration of dl-LacZ-DCNG resulted in greater transduction efficiency and viral spread throughout the tumor mass. Ad-ΔE1B-DCNG also enhanced viral distribution and tumor spread, leading to an increased anti-tumor effect and survival advantage. Upon histological analysis, Ad-ΔE1B-DCNG also elicited greater percentage of apoptotic cells and extensive necrosis compared to those from untreated or control virus-treated tumors. Furthermore, Ad-ΔE1B-DCNG substantially decreased extracellular matrix components within the tumor tissue, while normal tissue adjacent to the tumor was not affected. Finally, intratumoral administration of Ad-ΔE1B-DCNG did not enhance but inhibited the formation of pulmonary metastases of B16BL6 melanoma cells in mice. Taken together, these data demonstrate the utility of decorin as a dispersion agent and suggest its utility and potential in improving the efficacy of replicating adenovirus-mediated cancer gene therapy.
Introduction
Adenoviral vectors' inefficient ability to disseminate throughout tumor tissues remains a major obstacle in the development of a successful cancer gene therapy 1-6 .
Number of groups is seeking to address this problem by using oncolytic adenoviruses that selectively replicate in tumor cells. Bischoff and coworkers reported that by deleting an adenovirus early gene, E1B 55kDa, Ad selectively proliferated in cancer cells 7 . Subsequently in our previous report, we have shown that E1B 19kDa-and E1B 55kDa-double deleted replication-competent adenovirus, Ad-ΔElB19/55 (referred to as Ad-ΔE1B in this paper), induced viral cytolysis as well as E1A-mediated apoptosis, leading to an improved efficacy over E1B 55kDa-deleted replication-competent adenovirus, Ad-ΔElB55 8 .
Overall, selective replication and viral spread within cancer cells has seen some success, but the overwhelming promise that was once projected has not been fully realized mainly due to the uneven penetration and viral distribution of these engineered Ads within tumor tissues. To date, ONYX-015 (originally named dl1520), an E1B 55kD gene-deleted oncolytic adenovirus, has been tested in over 15 clinical trials in a range of tumor types 9, 10 , but only has reported limited success (7 to 14% local response rate) in patients with head and neck cancer, and worse no single agent efficacy was noted in other tumor types 11 . In preclinical xenograft tumor model studies, wild-type adenovirus has been shown to delay the growth of tumors, but rarely is able to eradicate established tumors. Recently, Sauthoff et al. demonstrated that high level of titratable Ads persisted within xenograft tumors for at least 8 weeks after intratumoral injection of the wild-type adenovirus 12 , but the pattern of viral distribution within the tumor tissue was uneven and patchy. The long-term viral persistence without complete responses suggests that viral spread maybe limited and that this limitation could be an important mechanism for the reported lack of efficacy.
Recent evidence has shown that connective tissue and extracellular matrix (ECM) may play a prominent role in inhibiting viral spread following their administration. First, Kuriyama et al. demonstrated that treatment with collagenase/dispase or trypsin prior to intratumoral injection of adenovirus, enhanced virus-mediated gene transduction 13 . Similarly, Maillard et al. elevated the efficiency of adenovirus-mediated gene transfer by about two-fold by treating rabbit iliac arteries with elastinase, an enzyme which dissociates elastin 14 . More recently, studies from our laboratory have demonstrated that ECM degradation by relaxin expressed from adenovirus increased viral spread throughout the tumor mass, resulting in an enhancement of transduction efficiency in solid tumors in vitro and in vivo 15 . Relaxin also demonstrated superior viral distribution of replicating oncolytic adenovirus, leading to an increased anti-tumor effect and survival advantage.
To extend our understanding of the role of the ECM barrier and connective tissue in inhibiting viral spread and penetration within tumor masses, we evaluated the utility of decorin. Decorin, a small leucine-rich proteoglycan, is a ubiquitous component of the ECM and is preferentially found in association with collagen fibrils 16 . Decorin binds to collagen fibrils and delays the lateral assembly of individual triple helical collagen molecules, resulting in the decreased diameter of the fibrils. Decorin may also affect the production of other ECM components by blocking the activity of transforming growth factor-β (TGF-β) 17 . Additionally, decorin can modulate the interactions of ECM components such as fibronectin and thrombospondin with cells. Furthermore, decorin is capable of affecting the ECM remodeling via induction of the matrix metalloproteinase collagenase (MMP-1) 16, 18 . These observations suggest that decorin regulates the production and assembly of the ECM at several levels and hence play a prominent role in remodeling connective tissues.
Given the importance of decorin's role in the ECM remodeling, we hypothesized that an increased expression of decorin would facilitate the spread of Ads within tumor tissues. We show here that expression of decorin dramatically increased the transgene expression and functionally, the dispersion of Ads within tumor tissues. As such the oncolytic potency of a decorin-expressing replicating adenovirus was significantly greater, both in vitro and in vivo. Taken together, these data demonstrate the utility of decorin as a dispersion agent, and suggest that decorin exhibits a high potential in improving the efficacy of replicating adenovirus-mediated cancer gene therapy.
Results

Construction of decorin-expressing adenoviruses and expression pattern of decorin
To evaluate role of decorin in altering tumor penetration efficiency, replicationincompetent dl-LacZ-DCNG, dl-LacZ-DCNQ, and dl-LacZ-DCNK adenoviruses expressing LacZ as a reporter were constructed. Tumor-specific replication-competent adenoviruses (Ad-ΔE1B-DCNG, Ad-ΔE1B-DCNQ, and Ad-ΔE1B-DCNK) were also constructed to enhance viral spreading into tissues. Point mutants of decorin gene, DCNK and DCNQ, contain substituted nucleotides at the region which plays a pivotal role in binding to type I collagen fibril. The first mutant, DCNQ, harbors a point mutation at the E180 amino acid site (E180Q), which is located in the sixth leucine-rich repeat of the wild type decorin core protein, and has a moderate binding affinity to type I collagen fibril. The second mutant, DCNK, also harbors an amino acid exchange at the amino acid E180 site but is substituted with lysine (K), resulting in lack of binding affinity to type I collagen fibril 19, 20 . To assess the activity of the adenoviruses, U343 cells were infected with replication-incompetent dl-LacZ-DCNG, dl-LacZ-DCNQ, and dl-LacZ-DCNK adenoviruses at 20 MOI or tumor-specific oncolytic adenoviruses Ad-ΔE1B, Ad-ΔE1B-DCNG, Ad-ΔE1B-DCNQ, and Ad-ΔE1B-DCNK at 5 MOI, and medium was then recovered for Western blotting. Cells infected with dl-LacZ or Ad-ΔE1B as negative controls for replication-incompetent adenovirus and tumor-specific oncolytic adenovirus were revealed not to express decorin, whereas all those infected with dl-LacZ-DCNG, dl-LacZ-DCNQ, dl-LacZ-DCNK, Ad-ΔE1B-DCNG, Ad-ΔE1B-DCNQ, and Ad-ΔE1B-DCNK showed decorin expression ( Fig. 1 ).
Evaluation on spreading and penetration potency of decorin-expressing adenoviruses to tumor tissue
In order to evaluate the penetration potency of decorin-expressing adenoviruses, U343 and U87MG tumor xenografts grown in nude mice were intratumorally injected with dl-LacZ or dl-LacZ-DCNG at 5 x 10 8 PFU for three injections. At 3 days post final adenoviral injection, tumor tissue was removed and stained for expression of βgalactosidase ( Fig. 2A ). While dl-LacZ exhibited low level of LacZ expression and the staining region was localized to the viral injection site, dl-LacZ-DCNG showed much higher LacZ expression and the stained region was found to be widely distributed other regions of the tumor. In comparison, both dl-LacZ-DCNK and dl-LacZ-DCNQ showed much lower LacZ expression was present in limited areas of the tumor. These results clearly demonstrate that tissue penetration potency of dl-LacZ-DCNG is greatly enhanced than those of dl-LacZ, dl-LacZ-DCNQ, and dl-LacZ-DCNK, and this enhanced tissue penetration effect derived from decorin-expressing adenovirus is dependent on the binding affinity of decorin to collagen fibril.
To further confirm the enhanced transduction efficiency and tissue penetration potency of wild-type decorin-expressing adenovirus, GFP-expressing adenoviruses (5 x 10 8 PFU of dl-GFP or dl-GFP-DCNG) were injected 3 times every other day into U87 tumor xenografts established in nude mice. Three days following the final injection, tumors were then harvested and photographed using a confocal microscope. As shown in Fig. 2B , we observed narrow path of fluorescence in the tumors infected with dl-GFP, which is assumed as a needle track formed when we injected viruses into tumors. In marked contrast, we observed fluorescence in more extended area of the tumor mass treated with dl-GFP-DCNG, and was not limited to sites of injections. Furthermore, to examine whether the enhanced transduction efficiency and tissue penetration potency of decorin-expressing adenovirus can also be translated to primary human tumor tissues, tumor spheroids were prepared from human patients with brain or breast cancers. The spheroids were transduced with LacZ-or GFP-expressing adenoviruses (1 x 10 7 PFU of dl-LacZ, dl-LacZ-DCNG, dl-GFP, or dl-GFP-DCNG).
Three days after viral infection, the tumor spheroids were then observed under a light or fluorescence microscope. As shown in Fig. 3 , LacZ or GFP expression was limited on the surface of primary tumor spheroids treated with either dl-LacZ or dl-GFP. In contrast, LacZ or GFP was strongly and widely expressed in most of tissues of the glioma and breast primary tumor spheroids treated with either dl-LacZ-DCNG or dl-GFP-DCNG. This profile of transduction efficiency and viral spread confirmed the observations noted from the in vivo experiments using human xenograft models.
Assessment decorin-expressing oncolytic adenovirus' ability to kill tumor cells
To link that the increase in spreading of decorin-expressing adenovirus contributes to enhanced tumor cell killing, an in vitro cytopathic effect assay was carried out. Two human glioma cell lines (U343 & U87MG) and human normal cell lines (CBHEL, IMR90, and WI38) were infected with dl-LacZ, Ad-ΔE1B, Ad-ΔE1B-DCNG, Ad-ΔE1B-DCNQ, or Ad-ΔE1B-DCNK adenovirus at MOIs of 0.1-20 for glioma cell lines and 0.1-100 for normal cell lines, and the tumor cell killing effect was analyzed. As shown in Fig. 4 , as expected, dl-LacZ had no effect in killing glioma cell lines. In contrast, Ad-ΔE1B-DCNG exhibited about 10-20 fold higher tumoricidal effect than Ad-ΔE1B control oncolytic adenovirus. This result was consistent over several independent experiments, indicating that decorin expression does not decrease the replication competency of adenoviruses and contributes to the dramatic increase in tumoricidal effect of adenoviruses as well. Interestingly, the tumoricidal effects of Ad-ΔE1B-DCNQ and Ad-ΔE1B-DCNK were decreased upon lowering the binding affinity to collagen compared to that of Ad-ΔE1B-DCNG. In marked contrast, Ad-ΔE1B-DCNG in normal cells showed no significant changes in cell killing effect compared to Ad-ΔE1B, highlighting the cancer specificity of this Ad.
Evaluation on anti-tumor efficacy of decorin-expressing oncolytic adenovirus in vivo
Wild-type decorin-expressing oncolytic adenovirus, Ad-ΔE1B-DCNG, was next examined for its ability to suppress the growth of human tumor xenografts, U343 and U87MG glioma models established in nude mice. Tumors were generated by subcutaneous injection of cells into the mice abdominal region. When tumors reached an average size of 70-100 mm 3 Similarly, Ad-ΔE1B-DCNG-treated U87MG glioma tumors also showed remarkable anti-tumor effect than those treated with Ad-ΔE1B, demonstrating that the decorinexpressing oncolytic adenovirus has stronger anti-tumor potency than Ad-ΔE1B. At 34 days after treatment for U87MG xenograft models, more specifically, Ad-ΔE1B and Throughout the course of the study, no systemic toxicity, such as diarrhea, loss of weight, or cachexia was observed. These results demonstrate that Ad-ΔE1B-DCNG can confer significant survival advantage and tumor reduction in vivo.
Change of tumor characteristics induced by decorin-expressing oncolytic adenovirus
The enhanced anti-tumor effect of decorin-expressing oncolytic adenovirus was further investigated by histological examination. Tumors were harvested from each treatment group at 3 days after the three sequential treatments. Hematoxylin and eosin (H & E) staining revealed that the majority of remaining tumor mass treated with Ad-ΔE1B-DCNG was necrotic, whereas necrotic lesions were only detectable in the limited region of tumors treated with Ad-ΔE1B ( Fig. 6A ). Viral distribution within the tumor mass was then confirmed by immunohistochemistry using an antibody specific to adenoviral hexon protein. Marked increase in number of adenoviral particles was detected in wider areas of Ad-ΔE1B-DCNG-treated U343 and U87MG tumors in comparison to Ad-ΔE1B-treated tumors. To analyze the degree to which Ad-ΔE1B-DCNG induced apoptosis in vivo, TUNEL assay was carried out. As seen in Fig. 6A , apoptotic level was significantly higher in Ad-ΔE1B-DCNG-treated tumor tissue than in PBS-or Ad-ΔE1B-treated tumor tissue, thus demonstrating that Ad-ΔE1B-DCNG adenovirus replicates actively in the viral injection site and spreads widely, contributing to the induction of apoptosis and necrosis.
Change of ECM components in tumor mass treated with decorin-expressing adenovirus
Tumor section slides from the tumor-bearing nude mice treated with Ad-ΔE1B or Ad-ΔE1B-DCNG were first stained using biebrich's scarlet acid fuchsin (Masson's trichrome stain) to analyze the distribution of collagen fibers (stained blue color), a major component of extracelluar matrix. As shown in Fig. 6B , U343 tumors treated with Ad-ΔE1B consisted of high content of collagen fibers (blue staining). In marked contrast, tumors treated with Ad-ΔE1B-DCNG appeared to be devoid of collagen fibers, indicating that decorin expression dramatically reduced the content of collagen fibers within the tumor mass. We further stained the tumor tissues with antibodies specific to collagen type I, collagen type III, and elastin. All these ECM components were prominent in the PBS-and Ad-ΔE1B-treated control tumor tissues, whereas almost no immunopositivity was observed in Ad-ΔE1B-DCNG-treated tumors, mirroring the findings with the Massons's trichrome staining. These results closely parallel and support the increased viral spread in the tumor mass and enhanced anti-tumor effect of decorin-expressing oncolytic adenovirus.
Inhibition of tumor metastasis by decorin-expressing oncolytic adenovirus
Since degradation of extracellular matrix has the potential to increase tumor metastasis, the impact of decorin expression on metastatic potential was examined using a spontaneous metastasis model. B16BL6 melanoma cells (1.5 x 10 5 /mouse) were implanted subcutaneously to form a local primary tumor on the right hind footpad of C57BL/6 mice, and metastases to distant organs were measured after the removal of the primary tumor. As shown in Fig. 7 , B16BL6 metastatic tumor nodules in the lung were considerably reduced by treatment with Ad-ΔE1B or Ad-ΔE1B-DCNG. The average number of metastasized nodules in the lung from mice treated with Ad-ΔE1B and Ad-ΔE1B-DCNG was 8.3 ± 2.4 and 2.3 ± 0.9 compared to PBS-treated control group (41 ± 8.2), translating to 80% (P < 0.01) and 94% (P < 0.01) inhibition, respectively.
Moreover, treatment with Ad-ΔE1B-DCNG further decreased pulmonary metastasis relative to Ad-ΔE1B, showing 72% inhibition (P < 0.05). These data indicate that the intratumoral injection of oncolytic adenovirus expressing decorin in primary tumor site greatly reduced and not enhanced the formation of metastatic lesions at distal sites compared to its cognate control oncolytic adenovirus in this model system.
Discussion
An important issue that has received little attention, but is fundamentally critical in improving viral-based cancer gene therapy, is the limited distribution of viruses within solid tumor tissues. Recent evidence has shown that connective tissue and ECM may play a prominent role in inhibiting viral spread. Harrison et al. showed that even though viable replicating viruses persisted within the bulk of the tumor, the connective tissue within established tumors hindered its spread and thus blocked complete tumor eradication 6 . Similarly, it has been shown that viral spreading is impaired by the presence of tumor-supporting structures 12 . Moreover, in a phase I clinical trial for recurrent glioma, it has been demonstrated that the zone of transduced cells did not extend beyond 5 mm from the site of injection 21 . To infect cells that are distally located from the site of viral inoculation, replicating adenovirus must transverse the extracellular space between cells and connective tissue. Therefore, strategies aimed at increasing the extent of anatomic distribution of replicating virus within a tumor mass would be desirable and timely.
To address this issue, we explored the use of decorin to enhance viral spreading Decorin has a high affinity binding site for TGF-β, so that binding of decorin to TGF-β neutralize its biological activity 17 . TGF-β is a pro-fibrotic cytokine that induces the accumulation of ECM via the inhibition of proteolytic enzymes and the enhancement of their tissue inhibitors. We found that TGF-β protein levels were reduced by decorin-expressing adenoviruses (dl-LacZ-DCNG & Ad-ΔE1B-DCNG) not only in U343 glioma cells but also in tumor tissues, supporting the notion that decorin is a natural inhibitor of TGF-β (Supplement Data. 1 & 2). In addition, the proteoglycan decorin is known to bind collagen fibrils near the d bands and delays the lateral assembly of collagen fibrils 16 . In accordance with these results, we observed that the level of collagen fibrils was significantly decreased in the tumor tissues treated with decorin-expressing adenovirus.
Finally, intratumoral administration of Ad-ΔE1B-DCNG did not enhance but inhibited the formation of pulmonary metastases of B16BL6 melanoma cells in mice.
Treatment with Ad-ΔE1B-DCNG resulted in a 94% inhibition (P < 0.01) of pulmonary metastases versus 80% (P < 0.01) for Ad-ΔE1B relative to PBS treatment, suggesting 1 6 that decorin-expressing oncolytic adenovirus can elicit potent anti-tumor efficacy not only against solid tumor but also against metastatic tumor lesions. Moreover, the therapeutic advantage of treatment with decorin-expressing oncolytic adenovirus demonstrated in this study using a murine spontaneous metastatic model would be greatly enhanced in a human system because human tumor cells are much more permissive to adenoviral infection and replication.
The pressing challenge for contemporary gene therapy is to deliver enough therapeutic genes to enough cancer cells in vivo. The application of decorin to enhance the ability of adenovirus to facilitate cell-to-cell dispersion resulted in significantly enhanced anti-tumor effect of replicating adenovirus in a variety of tumor xenograft models. This study is the first to report utilization of decorin to achieve therapeutic benefit with increased distribution of viral vectors in tumor tissues. In addition, we also demonstrate the usefulness of replication-incompetent adenovirus-mediated transfer of decorin as well as that of oncolytic adenovirus-mediated transfer of decorin. In summary, our findings presented here indicate that the expression of decorin may be a useful strategy in enhancing the efficacy of virus-mediated cancer gene therapy.
Materials and Methods
Cell lines and cell culture U343 and U87MG human glioma cell lines and HEK293 (human embryonic kidney cell line expressing the adenoviral E1 region) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL) supplemented with 10% fetal bovine serum (Gibco BRL), L-glutamine (2 mM), penicillin (100 IU/ml), and streptomycin (50 μg/ml). The murine B16BL6 melanoma cells 15 were grown in MEM supplemented with 5% FBS, vitamin solution (1 mM), sodium pyruvate (100 mM), nonessential amino acid (10 mM), penicillin (500 IU/ml), and streptomycin (50 μg/ml). All cell lines were maintained 37 o C in a humidified atmosphere at 5% CO 2 .
Experimental animals
In vivo anti-tumor experiments were conducted using 6-to 8-week-old male nude mice (BALB/c-nu) and C57BL/6 mice purchased from Charles River Korea (Seoul, Korea). All mice were maintained in a laminar air-flow cabinet under specific pathogen-free conditions. All facilities are approved by AAALAC (association of assessment and accreditation of laboratory animal care), and all animal experiments were conducted under the institutional guidelines established for the Animal Core Facility at Yonsei University College of Medicine.
Generation of decorin-expressing adenoviruses
To generate adenoviruses expressing decorin at the E3 region, wild-type and mutant decorin genes were first excised from pcDNA3.1-DCNG (containing the wild-type decorin cDNA), pcDNA3.1-DCNQ (containing mutant-type decorin cDNA having weaker binding affinity to collagen), and pcDNA3.1-DCNK (containing mutant-type decorin cDNA lacking binding affinity to collagen) 19, 20 
Evaluation on spreading and penetration of adenoviruses in vivo
To determine the extent of viral spreading and tumor penetration in vivo, U343 and U87MG human glioma xenografts were established subcutaneously by injecting cells into the abdomen of 6-to 8-week-old male nude mice. Once the tumors reached to 100-200 mm 3 in volume, mice were randomized and dl-LacZ, dl-LacZ-DCNG, dl-LacZ-DCNQ, or dl-LacZ-DCNK adenovirus at 5 x 10 8 PFU in 50 μl was intratumorally injected into the tumors three times, every other day. On day 3 after the last injection, animals were sacrificed and tumors were taken, after which they were fixed in 4% paraformaldehyde (PFA) at 4 for 4-8 hr and dehydrated in 30% sucrose solution for 12 hr. The dehydrated tumor tissues were embedded in O.C.T. compound and snap frozen.
Observance of blue staining with a light microscopy under low power was considered positive for β-galactosidase expression. Each experiment was carried out three to four times, and data from a representative experiment are shown.
Evaluation on transduction efficiency and tissue penetration potency of decorinexpressing adenoviruses using tumor tissues from breast cancer and glioma patient
Tumor tissues from breast cancer and glioma patients were freshly collected, cut into 1-2 mm sections and then plated onto HydroCell 12 Multi-well plates (CellSeed, Japan) after which they were cultured for 4 hr in IMDM (Isocove's Modified Dulbecco's Medium, Gibco BRL) supplemented with 5% FBS, 10 μM/L insulin and 1 μM/L hydrocortisone. Each of adenoviruses (dl-GFP or dl-GFP-DCNG for breast cancer spheroids and dl-LacZ or dl-LacZ-DCNG for glioma spheroids) at 1 x 10 7 PFU (breast cancer spheroids) or 1 x 10 8 PFU (glioma spheroids) were added into the plates containing primary tumor tissues, and incubated at 37 in 5% CO 2 incubator for 11 (breast cancer spheroids) and 3 (glioma spheroids) days. For the observation on penetration of adenovirus into tumor spheroid, the X-gal stained tumor spheroids were embedded in O.C.T. compound (Sakura Finetec) and snap frozen, followed by performing X-gal staining described above. The glioma spheroids were observed under a fluorescence microscope.
Anti-tumor effects and survival rates of decorin-expressing oncolytic adenovirus in vivo
Tumors were implanted on the abdomens of 5 to 6 week-old male nude mice by subcutaneous injection of 1 x 10 7 U343 and U87MG glioma cells in 100 μl of Hank's balanced salt solution (HBSS; Gibco BRL). When tumors reached a range of 70~100 mm 3 , animals were randomly assigned to one of three groups to receive PBS, Ad-ΔE1B, or Ad-ΔE1B-DCNG (seven or eight mice per group). The first day of treatment was designated as day 0. Adenovirus or PBS was administered intratumorally (5 x 10 8 PFU in 50 μl of PBS) on days 0, 2, and 4. Tumor growth delay was assessed by talking measurements every 2 or 3 days. The volume of tumors was calculated with the major axis and minor axis measured using a caliper: tumor volume = (minor axis mm) 2 x (major axis mm) x 0.523. The percentage of surviving mice was determined by monitoring the death of mice (for U87MG xenografts) or tumor growth related events (tumor size > 1500 mm 3 
for U343 xenografts)
Change of metastatic potential over decorin expression using spontaneous metastasis model
To assess changes of metastatic potential over decorin expression, B16BL6 cells (1.5 x 10 5 /mouse) were administered subcutaneously into the right hind foot pad of 6
week-old male C57BL/6 mice (Charles River Korea, Seoul, Korea) to form primary tumors. When the primary tumor reached a volume of about 200 mm 3 , animals were randomly assigned to one of three groups to receive PBS, Ad-ΔE1B, or Ad-ΔE1B-DCNG (six to eight mice per group). The first day of treatment was designated as day 0, and then 5 x 10 8 PFU per tumor in 50 ㎕ of PBS, mixed with Lipofectamine and Plus solution (Gibco BRL) at a 2 : 6 ratio or PBS was injected directly into the tumor on days 0, 2, and 4. On day 7, primary tumors were surgically removed by amputating the right hind leg below the knee under mild anesthesia. On day 28 after primary tumor lesions in the lungs of the mice was assessed.
Observation of the change of tumor characteristics induced by the administration of decorin-expressing adenovirus
Tumor tissue was fixed in 10% formalin, embedded in paraffin and cut into 3μm sections (Wax-it; Vancouver, Canada). Representative sections were stained with hematoxylin-eosin or with Masson's trichrome and then examined by light microscopy.
We used reagents supplied by DAKO ARK (Dako, Carpinteria, CA) to detect adenoviral antigens, as described previously 24 . The same paraffin slides were also used to identify apoptotic cells in tumors according to the instructions in the ApopTag kit for detecting cleaved deoxyribonucleic acids in situ with the TUNEL method. For the detection of collagen type I, collagen type III, and elastin in tumor tissues, paraffin tumor sections were first treated with monoclonal anti-collagen type I antibody (sc-25974; Santa cruz biotechnology), monoclonal anti-collagen type III antibody (C7805;
Sigma, St. Louis, MO), or monoclonal anti-elatin antibody (E4013; Sigma), and then with goat anti-mouse IgG-Biotin (sc-2039; Santa Cruz Biotechnology) as a secondary Three days after the last injection of adenoviruses, tumors were harvested and photographed with a confocal microscope. In the tumors treated with dl-GFP, we observed a narrow path of fluorescence that appeared to follow the needle track when we injected the viruses. In contract, in the tumors treated with dl-GFP-DCNG, fluorescence was distributed through the tumor mass. Original magnification: x 100. When the B16BL6 primary tumor reached a volume of about 200 mm 3 , PBS, Ad-ΔE1B, or Ad-ΔE1B-DCNG was administered intratumorally three times every other day. On day 7 after viral injection, the primary tumors were then surgically removed. On day 28 after primary tumor removal, the number of metastasized nodules in the lungs of the each mouse was counted and plotted. Each point represents the tumor nodules for every individual mouse (6 mice for PBS group, 7 mice for Ad-ΔE1B, and 8 mice for Ad-ΔE1B-DCNG) and the mean number of metastasized nodules for each group is shown with a line. *P < 0.01 vs. PBS-treated control and *P < 0.05 vs. Ad-ΔE1B-treated group.
Figure Legends
Supplement Data Legends
Supplement Data 1. Suppression of TGF-β expression in decorin-expressing adenovirus-treated glioma cells. U343 cells were transduced with either dl-LacZ or dl-LacZ-DCNG at different MOIs, and TGF-β expression was measured in the culture medium by conventional ELISA kits. The results showed a significant suppression of the TGF-β expression upon transduction with decorin-expressing adenovirus, whose levels decreased in a dose-dependent manner. 
